Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly.
Rheumatol Int
; 41(8): 1429-1440, 2021 08.
Article
em En
| MEDLINE
| ID: mdl-34109466
ABSTRACT
OBJECTIVE:
To assess antibody response to inactivated COVID-19 vaccine in patients with immune-mediated diseases (IMD) among hospital workers and people aged 65 and older.METHODS:
In this cross-sectional study, we studied 82 hospital workers with IMD (mean age 42.2 ± 10.0 years) and 300 (mean age 41.7 ± 9.9 years) controls. Among + 65 aged population, we studied 22 (mean age 71.4 ± 4.5 years) patients and 47 controls (mean age 70.9 ± 4.8 years). All study subjects had a negative history for COVID-19. Sera were obtained after at least 21 days following the second vaccination. Anti-spike IgG antibody titers were measured quantitatively using a commercially available immunoassay method.RESULTS:
Patients with IMD were significantly less likely to have detectable antibodies than healthy controls both among the hospital workers (92.7% vs 99.7%, p < 0.001) and elderly population (77.3% vs 97.9%, p = 0.011). Among patients with IMD, those using immunosuppressive or immune-modulating drugs (64/75, 85.3%) were significantly less likely to have detectable antibodies compared to those off treatment (29/29, 100%) (p = 0.029). Additionally, a negative association between age and the antibody titer categories among patients (r = - 0.352; p < 0.001) and controls (r = - 0.258; p < 0.001) were demonstrated.CONCLUSIONS:
Among hospital workers, the vast majority of patients with IMD and immunocompetent controls developed a significant humoral response following the administration of the second dose of inactivated COVID-19 vaccine. This was also true for the elderly population, albeit with lower antibody titers. Immunosuppressive use, particularly rituximab significantly reduced antibody titers. Antibody titers were significantly lower among those aged ≥ 60 years both in patient and control populations. Whether these individuals should get a booster dose warrants further studies.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Recursos Humanos em Hospital
/
Imunoglobulina G
/
Vacinação em Massa
/
Imunidade Humoral
/
Imunogenicidade da Vacina
/
Vacinas contra COVID-19
/
Doenças do Sistema Imunitário
/
Anticorpos Antivirais
Tipo de estudo:
Diagnostic_studies
/
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Asia
Idioma:
En
Revista:
Rheumatol Int
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Turquia